Henry, Kaplan's quote, which you posted, is ambiguous, especially for someone knowing little about the compounds ALRT326 and ALRT4204 themselves or about the nature of clinical trials involving the two. I believe you previously served up a web address that provides info on investigational compounds under study. Could you post that address again? Another line in the bw press release "Allergan will receive exclusive worldwide development, commercialization and sublicense rights to two promising second generation RXR selective compounds with potential application for metabolic diseases, ALRT 326 and ALRT 4204, subject to a 6 percent royalty payment to Ligand" also supports, IMO, the supposition that these two compounds may not necessarily be targeted at diabetes.
What evidence is their to suggest that AGN would want to do a diabetes deal and by doing so place themselves in a position to go head to head with LGND in the DM arena? Briefly, what is, and what is likely to be, AGN's strategic focus? From what I know it looks like they've got strength in dermatologics. What else? |
